# Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

> **NCT00238420** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Bladder Urothelial Carcinoma
- Stage I Bladder Cancer AJCC v6 and v7
- Stage II Bladder Cancer AJCC v6 and v7
- Stage III Bladder Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Paclitaxel
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT00238420
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-26
- **Primary completion:** 2014-02-05
- **Final completion:** 2022-05-20
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238420, "Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00238420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*